# Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

> **NCT00553462** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 78 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** erlotinib hydrochloride
- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00553462
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2014-01
- **Final completion:** 2017-06-15
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553462, "Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00553462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*